Patients receiving opioids for pain may experience decreased effectiveness of the drug and even abnormal pain sensitivity-hyperalgesia and/or allodynia. We hypothesized that peripheral nociceptor hyperexcitability contributes to opioid-induced hyperalgesia and tested this using an in vitro mouse glabrous skin-nerve preparation. Mice were injected intraperitoneally with escalating doses of morphine (5, 8, 10, 15 mg/kg) or saline every 12 hours for 48 hours and killed approximately 12 hours after the last injection.
Introduction
Patients receiving opioids for pain management may experience abnormal pain sensitivity-hyperalgesia (increased pain from a stimulus that normally provokes pain) and/or allodynia (pain due to a stimulus that does not normally provoke pain) [72] . Opioid-induced hyperalgesia (OIH) is defined in animal studies as a decrease of pain threshold from baseline after chronic administration of opioids. OIH has been reported in animal studies over the last 3 decades [4] . For many years, the clinical community perceived OIH as a phenomenon of preclinical research and not relevant to the clinic [82] . In recent years, OIH has been recognized as a real syndrome needing to be addressed in humans, although there is still no well-accepted definition of OIH in the clinic [82] . It is commonly identified by the decreased analgesic effect of opioid drugs, or a rebound increase in pain sensitivity that develops over a course of opioid treatment [4] . However, hyperalgesia also occurs with the development of tolerance to opioids and as part of the withdrawal syndrome, thus clinical OIH in the absence of either tolerance or withdrawal has been difficult to establish. Increased pain over the course of opioid treatment in the absence of withdrawal could likely reflect either the development of tolerance (a desensitization process) or an elevation of pronociception (a sensitization process), among other possibilities [7] . In a clinical setting, tolerance can be treated by increasing the opioid dosage, thus reinstating pain relief. By contrast, if a patient is experiencing OIH, increasing the opioid dose may worsen the patient's condition by increasing sensitivity to pain. In addition, increasing the opioid dose without concomitant pain relief can escalate physical dependence and increase the probability of abuse [27] . Thus, OIH is an important clinical issue; however, its underlying mechanisms are poorly understood.
Several molecular mechanisms have been proposed to explain the development of OIH and sensitization including: (1) sensitization of primary afferent neurons, (2) enhanced production and release of excitatory neurotransmitters or suppressed reuptake of these transmitters, (3) sensitization of second-order neurons, (4)
